Mitochondria are ubiquitous intracellular organelles that play a pivotal role in cellular energy metabolism. It therefore should come as no surprise that mitochondrial dysfunction can cause neurological disease. These disorders are not rare; each UK neurologist will have at least 20 patients with mitochondrial disease within their catchment area of about 200 000 people. This short article will focus on the basic science that underpins our current understanding of mitochondrial disease. It will stick to the bare essential facts that will help the busy neurologist to identify, investigate and manage these fascinating and challenging patients.
The tables should serve as a useful reference. Table 1 illustrates the clinical relevance of the basic science described in this article, but the reader should be aware that it will soon be out of date. Table 2 lists the features associated with well-recognized mitochondrial 'syndromes' .
MITOCHONDRIA AND MITOCHONDRIAL DISORDERS: WHAT ARE THEY?
Rather than thinking of mitochondria as discrete membrane-bound structures, they probably form a budding and fusing reticulum that is integrated into the cellular network. Mitochondria have a number of interrelated functions. They are involved in intracellular calcium sig-
The respiratory chain has a dual genetic basis. The vast majority of the respiratory chain complex subunits are synthesized within the cytoplasm from nuclear gene transcripts (messenger RNA molecules transcribed from genes within the cell nucleus). These are delivered into mitochondria by a targeting sequence that enters through the mitochondrial protein import machinery. Thirteen of the complex subunits are synthesized within the mitochondria themselves from small circles of DNA called the mitochondrial genome (mtDNA; Fig. 2 ). In addition to the protein coding genes, mtDNA also encodes for 24 RNA molecules that are needed for intramitochondrial protein synthesis. As a result, genetic mutations of nuclear DNA (nDNA) or mtDNA can affect respiratory chain activity. MtDNA defects fall into two groups: rearrangements (large chunks of deleted or duplicated mtDNA) and point mutations (single base changes). These mutations can affect the RNA genes and lead to a general defect of protein synthesis within the mitochondria, or they can affect the protein-encoding genes themselves. MtDNA duplications are often found in patients harbouring mtDNA deletions, but the duplications are not thought to be pathogenic.
Mitochondria cannot survive on their own, and there are many nuclear-encoded factors that play a crucial role in maintaining a healthy respiratory chain. Over recent years we have learned that these factors are important clinically. The nucleus maintains healthy mtDNA thoughout human life. Disruption of the mtDNA polymerase-γ (POLG), or the balance of nucleotides (DNA building blocks) within the mitochondrial matrix, leads to the formation of many different secondary mutations of mtDNA throughout life, or the loss (depletion) of mtDNA (Table 1 , disorders of mtDNA maintenance). Finally, specifi c proteins are needed to assemble the various components of the respiratory chain into the complete complexes, and disruption of these processes can also lead to severe respiratory chain defi ciencies that usually present in childhood (Table 1 , disorders of assembly of the respiratory chain).
Two other mitochondrial components also need mentioning. Co-enzyme Q10 Figure 1 Nuclear -mitochondrial interactions and the respiratory chain. The mitochondrial respiratory chain consists of fi ve enzyme complexes that use the products of intermediary metabolism (of proteins, carbohydrates and fats) to synthesize adenosine triphosphate (ATP) which is shuttled out of the mitochondria by adenine nucleotide transferrase (ANT). MtDNA is maintained by a number of nuclear encoded factors. Nuclear factors also regulate the transcription of mtDNA (forming a messenger RNA template) and the translation of the transcripts into proteins within the mitochondrion. Nuclear DNA also codes for most of the respiratory chain subunits and the complex assembly factors. MtDNA codes for 13 essential respiratory chain subunits and part of the machinery needed for protein synthesis within the mitochondrial matrix. e -, electrons; Q, coenzyme Q10 (ubiquinone).
group.bmj.com on August 27, 2017 -Published by http://pn.bmj.com/ Downloaded from ( ubiquinone) has an important role shuttling electrons between different respiratory chain complexes, and which adenine nucleotide transferrase (ANT) exchanges ATP and ADP across the mitochondrial membrane.
MITOCHONDRIAL DNA, HETEROPLASMY AND THE THRESHOLD EFFECT
Mononuclear human cells contain only two copies of each nuclear gene, but many thousands of copies of mtDNA. At birth all the mtDNA molecules are identical (a situation called homoplasmy). Patients with pathogenic mtDNA defects usually harbour a mixture of mutant and wild-type (normal) mtDNA within each cell (heteroplasmy). The proportion of mutant mtDNA can vary between 1 and 99%, and the cell only expresses a biochemical defect when the proportion of mutant mtDNA exceeds a critical threshold (typically 50-80% mutant, depending on the exact genetic defect).
TISSUE SPECIFICITY…GETTING MORE COMPLICATED
Perhaps the most diffi cult thing to explain is the relative selectivity of clinical involvement. Although the traditional view is that mitochondrial disorders can affect any organ system this is not strictly true, and certain tissues seem to be preferentially involved. In simple terms, tissues and organs that are heavily dependent upon ATP appear to be preferentially involved in patients with mitochondrial diseases. Neurones appear to be particularly vulnerable (including the retina and optic nerve), followed by skeletal and cardiac muscle, and endocrine organs (particularly the endocrine pancreas). However, a wide range of tissues may be involved including the cochlea, the gastrointestinal tract, the skin and haematological tissues.
Patients with mtDNA disease have the added complexity of mtDNA heteroplasmy. Different levels of mutant mtDNA in different tissues, coupled with tissue specifi c thresholds, partly explains the pattern of clinical involvement. However, if it were that simple then all patients with mitochondrial disease would look the same in the clinic -something that is clearly not the case.
PHENOCOPIES AND PHENOTYPIC VARIATION
To pick an example, the A3243G point mutation of mtDNA characteristically causes mitochondrial encephalopathy with lactic acidosis and group.bmj.com on August 27, 2017 -Published by http://pn.bmj.com/ Downloaded from stroke-like episodes (MELAS). This mutation affects a mitochondrial tRNA gene that impairs the synthesis of respiratory chain proteins within mitochondria and it is invariably heteroplasmic. The A8344G point mutation of mtDNA causes myoclonic epilepsy with ragged-red fi bres (MERRF) and also affects a mitochondrial tRNA gene with a consequent reduction in intramitochondrial protein synthesis, and it is also invariably heteroplasmic. Although there is some clinical overlap in the phenotypes associated with these two mutations, they often cause quite different disorders (Table 2 ), despite the fact that the molecular defects are strikingly similar.
Unfortunately there is a poor relationship between the clinical features of mitochondrial disease and the underlying genetic and biochemical abnormalities. Different genetic defects can cause a similar clinical phenotype (for example, a mutation in mtDNA or nDNA can cause clinically indistinguishable Leigh's syndrome), and yet the same genetic defect can also cause very different clinical features even within the same family (for example A3243G can cause MELAS, but more often causes a milder disorder with deafness, diabetes or external ophthalmoplegia with ptosis). It is becoming clear that additional mitochondrial and nuclear genetic factors modulate the expression of the primary mtDNA defects, and that these interact with the environment. We clearly do not have all the answers at present.
Despite the complexities, there are, however, a number of well recognised syndromes that are usually due to mitochondrial disease (Table 2) . However, mitochondrial dysfunction should be considered in any patient with an unexplained neurological disorder along with multiple additional organ involvement.
PROBLEMS WITH MAKING A MOLECULAR DIAGNOSIS
If a patient has a suspected nuclear mitochondrial disorder, then DNA analysis can be carried out on a blood sample. In some patients with a mtDNA mutation it may be possible to identify the genetic defect in a blood sample (for example, in patients with Leber's hereditary optic neuropathy where most patients have only mutant mtDNA -homoplasmic mutant). Unfortunately a simple blood sample may not be suffi cient when investigating every patient with suspected mitochondrial disease. This is because the level of mutant mtDNA may be very low in blood (below the threshold of detection), or not present at all. This is almost always the case in patients with sporadic chronic progressive external ophthalmoplegia or the Kearns-Sayre syndrome, which is usually due to a mtDNA deletion, but it also applies to point mutations such as the common A3243G mutation. Thus, whilst it is entirely reasonable to send off a blood sample for molecular analysis in patients with suspected mitochondrial disease, if the blood mtDNA test is negative the patient should then have a muscle biopsy.
CLUES FROM THE HISTOCHEMISTRY
Routine muscle histochemisty includes a reaction for COX and SDH (Fig. 3) . COX has both nuclear and mtDNA encoded subunits. A generalized decrease in COX in all muscle fi bres suggests that the genetic defect is in the nuclear genome, probably involving a COX group.bmj.com on August 27, 2017 -Published by http://pn.bmj.com/ Downloaded from assembly gene. Patients with mtDNA defects often have a mosaic COX defi ciency (Fig. 3) because different muscle fi bres contain different amounts of mutant mtDNA and only some fi bres contain supra-threshold levels. SDH is the only respiratory chain complex that is entirely encoded by nuclear genes. Patients with mtDNA mutations usually show up-regulation of SDH in affected fi bres (thought to be a compensatory mechanism) and proliferation of mitochondria (corresponding to ragged red-fibres, Fig. 3 ). Unfortunately some patients have a biochemical defect that does not involve SDH or COX, and these patients have normal muscle histochemistry. As luck would have it, the most common heteroplasmic mtDNA point mutation (the A3243G 'MELAS' mutation) does just this. So, normal muscle histochemistry does not mean no mitochondrial disease. If a mitochondrial disease is still high on the list of differential diagnoses, then the next step is to measure individual respiratory chain complexes in muscle. This is only done well in a few specialist centres.
INHERITANCE
The nuclear genetic mitochondrial disorders are inherited as autosomal dominant, autosomal recessive or rarely as X-linked recessive traits (Table 1) . By contrast, mtDNA is inherited down the maternal line. This means that a male cannot transmit the defect to their offspring -information that is always received by families with great relief. The offspring of women with a mtDNA defect are at risk of inheriting the disorder. Approximately one-third of pathogenic mtDNA defects are deletions, and the risk of women transmitting mtDNA deletions is low (< 1%, the reasons for this are not known). Approximately one-third of pathogenic mtDNA defects are homoplasmic (i.e. all of the mtDNA is mutant). In this situation, a woman will pass on the defect to all her offspring who will also be homoplasmic (this is usually the case for Leber's hereditary optic neuropathy, where about 40% of male offspring and 10% of female offspring become affected). For the remaining one-third, the mutation is heteroplasmic and a varying proportion of mutant mtDNA may be passed on to the offspring. The inherited mutation load roughly correlates with the likelihood of becoming clinically affected. There are no robust counselling guidelines available for women with heteroplasmic mtDNA mutations. This is an area of current study.
ANY TREATMENTS?
There are currently no established disease modifying treatments for mitochondrial disease. Patients are often given ubiquinone (coenzyme Q10) because it is innocuous and there have been reports of improvement in some cases. Various vitamins and cofactors have also been used, and there is a clinical trial of dichloracetate currently in progress. Management is largely supportive, with particular attention being paid to genetic counselling.
CONCLUSION
Although mitochondrial disease is confusing, it is relatively straightforward to avoid the clinical pitfalls if a few basic facts are kept in mind (see text in box). We may have no treatments, but a precise diagnosis has important implications for the management of these patients who are being increasingly recognized.
